C. Curtis

发表

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Tae Min Kim, Bruce E Johnson, Harry J M Groen, 2016, The Lancet. Oncology.

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

J. Falloon, M. Esser, H. Talbot, 2017, Clinical and Vaccine Immunology.

Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).

H. Groen, J. Rigas, D. Planchard, 2015 .

Non-invasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer

E. Bowman, M. Haznadar, P. Shields, 2014 .

LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)

M. Socinski, E. Smit, Gregory Riely, 2014 .

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.

J. Falloon, M. Esser, F. Dubovsky, 2016, Vaccine.

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

C. Rudin, M. Socinski, Gregory Riely, 2013 .

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

M. Brown, R. Kurzrock, J. Infante, 2012, The Lancet.

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

Tom Mikkelsen, Patrick Y Wen, Jorge Barriuso, 2013, Clinical Cancer Research.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

R. Govindan, F. Hirsch, M. Brown, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus

K. Grebe, S. Wong, R. Fleischmann, 2018, Lupus.

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).

J. Infante, M. Millward, R. Kefford, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT

T. Marbury, A. Mathias, D. Brainard, 2014 .

Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment

K. Lasseter, T. Marbury, A. Mathias, 2018, Clinical Pharmacokinetics.

A phase I study of pazopanib in patients with advanced hepatocellular carcinoma.

R. Poon, P. Murphy, A. Suttle, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics

T. Yau, R. Poon, P. Murphy, 2011, Clinical Cancer Research.